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It  is  clinically  important  to  differentiate  focal  nodular  hyper-
plasia  (FNH)  from  inﬂammatory  hepatocellular  adenoma
(IHCA)  because  FNH  does  not  need  surgical  resection.  How-
ever,  these  two  types  of  benign  liver  tumors  may  share
some  pathological  similarities,  at  least  in  some  areas.
In  a  recent  article  published  in  Modern  Pathology  [1],
authors  from  three  different  US  academic  centers  (San
Francisco,  Baltimore  and  Seattle)  studied  the  diagnostic  util-
ity  and  limitations  of  glutamine  synthetase  (GS)  and  serum
amyloid-associated  (SAA)  protein  immunohistochemistry  in
the  distinction  of  FNH  from  IHCA.  Standard  histology  and
immunohistochemistry  were  analyzed  in  54  IHCA,  40  FNH,
and  3  indeterminate  lesions.  Their  results  are  summarized  in
Table  1.  Before  going  into  the  analysis  of  the  results  of  this
study,  it  is  important  to  remind  that  the  interpretation  of
immunohistochemistry  (IHC)  is  based  on  molecular  data  [2].
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FNH
Gene  expression  studies  have  revealed  molecular  features
supporting  the  theory  of  vascular  abnormalities  as  a  driv-
ing  event  in  the  formation  of  FNH.  Indeed,  FNH  present
abnormal  expression  of  genes  involved  in  angiogenesis
with  an  increase  in  expression  of  the  ANGPT1/ANGPT2
ratio  [2].  Another  major  ﬁnding  is  the  overexpression  of
Wnt/b-catenin  target  genes,  including  GLUL  [3]  coding
for  glutamine  synthetase  (GS).  In  a  normal  liver  lobule,
GS  is  expressed  only  in  2  to  3  hepatocyte  layers  around
the  central  vein.  In  contrast,  in  FNH,  there  is  an  over-
expression  of  GS  that  shows  a speciﬁc  location  with  a
map-like  pattern  predominantly  in  the  periphery  of  the  nod-
ules  [4]. This  heterogeneous  distribution  of  GS  is  caused
by  b-catenin  activation  without  b-catenin  mutations,  in
accordance  with  the  polyclonal  origin  of  FNH  [3]. Despite
the  fact  that  GS  staining  is  a  major  marker  to  identify
FNH,  the  map-like  pattern  may  be  missing  in  rare  cases,
or  difﬁcult  to  interpret  (especially  in  biospies),  the  ﬁnal
conclusion  relying  then  on  additional  markers  such  as  CK7  as
well  as  on  the  elimination  of  well-identiﬁed  HCA  subtypes
[5].
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Table  1  Immunohistochemistry  data  (GS  and  SAA)  in  FNH  and  IHCA  obtained  in  the  article  [1].
SAA  GS
Tumor  (54  cases)
IHCA  Negative  2/53  (4%)
Positive  50/54  (93%)  Perivascular  and/or  patchy  39/53  (74%)
Focal 6/54  Pseudo  map-like  8/53  (15%)
Diffuse 44/54 Classical  map-like:  0/54
Negative  4/54  (should  be  4  and  not  8) Diffuse  4/53  (8%);  3  b-cat  positive
Non-tumoral  liver  (23  cases)
Positive  14/23  (61%)  but  less  intense  than  in  tumor Normal  staining  in  perivenular  area
Tumor (40  cases)
FNH  Classical  map-like  36/40  (90%)
Positive 7/40:  2  patchy,  5  diffuse  Pseudo  map-like  4/40  (10%)  all  on  biopsies
Negative 33/40  (83%)
Non-tumoral  liver  (9  cases)
Positive  5/9  (56%)  Normal  staining  in  perivenular  area
3 cases  with  no  staining  in  the  tumor
2 cases  with  the  same  level  than  in  the  tumor
GS: glutamine synthetase; SAA: serum amyloid-associated; FNH: focal nodular hyperplasia; IHCA: inﬂammatory hepatocellular adenoma.
FNH-like nodules
Classically  they  are  large  regenerative  nodules  (a  differ-
ent  entity  from  FNH)  described  in  cirrhotic  patients,  and
presenting  an  immunohistochemical  proﬁle  similar  to  that
of  other  cirrhotic  samples  and  different  from  typical  FNH
[3].  In  particular,  in  FNH-like  nodules,  b-catenin-induced
perivenous  GS  is  signiﬁcantly  down  regulated  compared  to
non-tumoral  liver  and  FNH  [3].  Consistent  with  this  result,
very  little  parenchymal  GS  staining  is  observed  in  FNH-like
nodules  [3];  however,  in  rare  cases,  GS  staining  is  occa-
sionally  mildly  positive,  resembling  FNH  [6].  Notably,  in  the
ﬁnal  stage  of  cirrhosis,  GS  is  barely  detectable  in  nodules,
whereas  in  the  early  stage  of  compensated  cirrhosis,  GS
expression  is  quasi  normal  [7].  In  addition,  the  expression
of  C  reactive  protein  (CRP)  in  FNH-like  nodules  is  either
absent  or  weak,  focally  or  diffusely  [6].  CRP  an  inﬂammatory
protein  is  used  to  identify  inﬂammatory  HCA  (see  below).
Inﬂammatory HCA (IHCA)
The  main  feature  of  IHCA  is  the  activation  of  the  JAK/STAT
pathway  [2].  Five  different  molecular  drivers,  namely  IL6ST
(coding  for  gp130),  STAT3,  GNAS,  Jak1  and  FRK  were  dis-
covered  as  oncogenes  activated  by  mutations  in  IHCA  [2,8].
Each  mutation  is  exclusive  from  the  others  and  the  differ-
ent  mutated  genes  can  explain  more  than  80%  of  the  overall
IHCAs.  So,  in  approximately  20%  of  IHCAs,  no  gene  defect
that  could  explain  the  inﬂammatory  phenotype  has  been
identiﬁed  so  far.
In  general,  the  recent  paper  of  Joseph  et  al.  [1]  who
quantiﬁed  IHC  data  in  FNH  and  IHCA  conﬁrms  previous  data
showing  the  progress  made  in  the  discrimination  of  FNH  from
IHCA  using  GS  for  the  identiﬁcation  of  FNH  and  inﬂammatory
proteins  (serum  amyloid  A  [SAA]  or  CRP)  for  the  identiﬁca-
tion  of  IHCA  (Table  1).  The  authors,  however,  pinpoint  the
limits  of  the  results  obtained  with  the  2  markers  (GS  and
SAA)  they  used,  and  the  pitfalls  in  the  identiﬁcation  of  the
2  types  of  nodules  (see  Table  5  of  ref  [1]).
There  are  several  explanations  for  these  results:
•  as  molecular  biology  cannot  be  used  in  routine  practice,
IHC  is  a  valid  and  robust  surrogate  technique.  However,
the  interpretation  of  IHC  should  correspond  to  strict  well-
deﬁned  criteria  [5]. The  criteria  deﬁned  in  this  paper  have
not  yet  been  validated;
• IHC  interpretation  is  based  on  the  comparison  between
tumoral  and  non-tumoral  livers.  However,  in  this  study,
non-tumoral  tissues  were  available  in  only  23/54  IHCA  and
9/40  FNH,  respectively.  It  is  also  necessary  to  avoid  any
misinterpretation  related  to  rare  technical  problems;
•  it  is  easy  to  understand  that  IHC  interpretation  is  more
difﬁcult  in  liver  biopsy;
•  the  lack  of  information  related  to  background  liver  dis-
ease;
•  the  partial  lack  of  basic  clinical  (age  and  gender  were
available  in  43/54  IHCA  and  35/40  FNH,  no  information
on  liver  disease,  etc.),  biological,  radiological  and  patho-
logical  data  particularly  the  size  of  the  tumor,  and/or  the
length  and  diameter  of  the  biopsy,  evidence  of  remod-
eling  by  bleeding,  necrosis.  In  remodeled  HCA,  ﬁbrotic
bands  with  some  degree  of  ductular  reaction  are  not  rare
creating  occasionally  confusion  with  FNH.
In  our  institution,  interpretation  of  IHC  is  based  on  molec-
ular  data  as  much  as  possible  [5]  (Table  2)  as  described
below.
SAA or CRP staining interpretation
In  HCA
Positive  staining  is  interpreted  as  a  surrogate  marker  of
IHCA  [2,5]. In  the  paper,  the  authors  scored  positivity  from
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Table  2  Our  personal  data  interpretation  of  immunohistochemistry  (GS  and  CRP)  in  FNH  and  IHCA  developed  in  a  normal  livera.
CRP  GS
Tumor
IHCA  Negativity
Positivity  diffuse  (positivity  is  the  hallmark  of  the
diagnosis)  [9]  (variable  intensity,  but  usually  strong;  in
case of  extremely  weak  CRP  staining  the  diagnosis  of
IHCA cannot  be  made  without  searching  for  mutations
[MB])
Hepatocytes  surrounding  veins  [9]  can  be  positive  as
well as  the  periphery  of  the  tumor  (unknown  meaning)
CRP cannot  be  interpreted  if  CRP  is  positive  in  NT
[9]
Faint  background  staining  (diffuse  or  focal)  is  difﬁcult
to interpret  as  possibly  related  to  b-cat  mutations
(usually  negative  by  IHC)  need  for  MB
Atrophic hepatocytes  (major  sinusoidal  dilatation)
can be  CRP  negative
Strong:  see  b-IHCA  below
Non-tumoral  liver
Negativeb Normal  perivenular  staining
Weak centrolular  staining  can  be  observed  (no
diagnosis  implication)
b-IHCA
As  above Diffusely  homogeneously  positive,  b-catenin  often  +
good  correlation  with  b-catenin  mutations  (MB)
Patchy  [9]  (from  mild  to  strong,  usually  diffuse)
correlation  with  b-catenin  mutations  is  not  yet  well
establish,  except  if  b-catenin  staining  is  positive
Tumor
FNH [4]
Negative  (negativity  is  one  of  the  hallmark)  Positive  (classical  map-like  [staining  mild  to  strong
and more  or  less  spread  within  the  nodule])
CRP is  often  focally  positive  around  Inﬂammatory
cells (no  diagnosis  implication)
Negativity  (particularly  on  a  biopsy)  does  not
eliminate  the  diagnosis  (sampling  problem)
CRP can  be  positive  in  case  of  a  generalized
inﬂammatory  stateb
Non-tumoral  liver
Negativeb Normal  perivenular  staining
Weak centrolobular  staining  can  be  observed  (no
diagnosis  implication)
GS: glutamine synthetase; CRP: C reactive protein; FNH: focal nodular hyperplasia; IHCA: inﬂammatory hepatocellular adenoma; MB:
molecular biology; NT: non-tumoral liver.
a Data in the cirrhotic liver may be different.
b Can be positive in particular cases (portal embolization. . .).
0  to  3  (0  absent,  3  strong)  and  classiﬁed  SAA  positivity  as
focal  <  50%  and  diffuse  >  50%.
In  our  hands,  the  staining  is  positive  (from  mild  to  strong)
or  negative;  diffuse  positivity  means  close  to  100%  positivity
and  focal  positivity  means  expression  around  inﬂammatory
cells,  a  frequent  ﬁnding  in  FNH  and  HCA  which  is  not  consid-
ered  signiﬁcant  for  the  diagnosis  of  either  nodules.  CRP  has
always  been  more  reliable  than  SAA  in  our  experience.  In
addition,  so  far,  CRP  negative  nodule  has  never  been  proven
to  be  IHCA  by  molecular  biology.
In  FNH
A  diffuse  positive  immunohistochemical  expression  of  CRP
or  SAA  in  FNH  is  puzzling  if  the  non-tumoral  liver  is  neg-
ative,  and  we  have  never  seen  such  a  case.  By  contrast,
positive  staining  of  CRP  or  SAA  in  the  non-tumoral  liver
may  occur  and  this  excludes  totally  the  interpretation  of
their  positivity  in  the  tumor  (FNH  or  HCA).  Indeed  a  posi-
tive  CRP  staining  is  observed  in  the  non-tumoral  liver  after
portal  vein  embolization,  or  bleeding  and,  probably,  in  all
circumstances  in  which  there  is  an  inﬂammatory  syndrome
[9]; therefore,  the  positivity  in  the  non-tumoral  liver  has  not
the  same  physiopathological  meaning  than  in  the  tumor.
GS staining interpretation
In  HCA,  GS  is  interpreted  as  a  surrogate  marker  of  b-catenin
mutation  [2,5].
The  distinction  between  perivascular  on  one  hand,  and
patchy  and  perivascular  on  the  other  hand,  as  described  in
this  paper,  either  in  FNH  or  IHCA  [1]  seems  confusing.  Indeed
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we  do  not  know  if  it  makes  sense  to  interpret  GS  in  IHCA  as
in  the  normal  liver.  In  IHCA,  GS  staining  goes  from  absent,
to  few  hepatocytes  in  one  single  row  to  several  rows  of
hepatocytes,  always  around  veins.  It  can  also  be  strong  and
diffuse  indicating  therefore  a  beta-catenin  activated  IHCA
(b-IHCA).  ‘‘Perivascular  and/or  patchy  staining  (predom-
inantly  perivascular  or  perivascular  staining  accompanied
by  staining  of  variable  intensity  in  clusters  of  hepatocytes
beyond  the  perivascular  region)’’  as  deﬁned  by  Joseph  et  al.,
has  to  our  knowledge  no  speciﬁc  meaning  sustained  by
molecular  data.
The  term  patchy  [9]  has  been  previously  used  when  the
staining  was  irregularly  dispersed  in  the  whole  tumor  (not
only  perivascular),  with  a  variable  intensity,  and  with  the
understanding  that  it  could  be  linked  to  b-catenin  muta-
tions,  in  spite  of  the  fact  that  b-catenin  nuclear  staining  was
often  absent.  Molecular  studies  are  still  ongoing  to  under-
stand  this  ﬁnding.
The  real  problem  concerns  GS  ‘‘pseudo  map-like  stain-
ing’’.  For  the  authors  it  means  a  staining  in  clusters  of
hepatocytes  beyond  the  perivascular  region  showing  inter-
connected  areas.  It  differs  from  the  classical  map-like
staining  in  three  aspects:
•  the  positive  interconnected  bands  of  hepatocytes  are  nar-
row  and  inconspicuous;
•  staining  intensity  is  variable,  typically  mild  to  moderate,
and  fades  in  intensity  away  from  perivascular  areas;
•  the  staining  is  focal  and  conﬁned  to  periphery.
Anything  focal  and  localized  at  the  periphery,  in  our  expe-
rience,  should  be  interpreted  cautiously  and  should  not  lead
to  a  speciﬁc  category  of  lesions  until  proven  to  be  related  to
b-catenin  mutations  by  molecular  biology.  Furthermore  it  is
necessary  to  take  into  account  the  possibility  of  peritumoral
hyperplasia  as  suggested  by  the  work  of  Wanless  et  al.  [10].
From  what  has  been  mentioned  above,  it  is  obvious  that
the  interpretation  of  GS  and  CRP/SAA  staining  can  already
be  difﬁcult  in  surgical  specimen,  so  even  more  difﬁcult  on  a
biopsy  [11]  and  all  kinds  of  misinterpretation  (summarized
in  Table  5 of  ref  [1])  can  be  considered  if  the  interpretation
does  not  take  into  account:
• the  pathomolecular  relationships;
•  the  geographical  distribution  of  the  markers;
•  the  staining  of  the  background  liver.
Not  surprisingly  there  are  still  indeterminate  lesions  that
require  molecular  analysis.  In  this  article,  three  cases  could
not  be  classiﬁed  as  FNH  or  IHCA  and  were  labeled  as  inde-
terminate.  In  these  3  cases,  SAA  staining  was  positive  and
GS  presented  a  pseudo  map-like  staining.  To  our  opin-
ion,  these  nodules  require  further  investigations  (including
CRP  immunostaining)  before  to  conclude  to  indeterminate
lesions.
It  is  important  in  clinical  practice  to  proceed  step-by-step
with  IHC,  as  previously  described  [12].  In  addition,  we  prefer
to  perform  CRP  staining,  alone  or  in  association  with  SAA,
particularly  if  SAA  staining  is  not  straightforward.  To  extend
the  discussion,  the  interpretation  of  GS  and  CRP  staining  to
differentiate  FNH  from  IHCA  is  not  a  major  issue  in  our  expe-
rience.  The  main  issue  remains  the  differential  diagnosis
between  FNH  without  typical  map-like  pattern  of  GS  staining
and  unclassiﬁed  HCA  (particularly  when  they  are  remodeled)
with  some  pathological  features  observed  in  FNH.
In  conclusion:
•  the  ﬁnal  diagnosis  of  FNH  or  HCA  must  be  made  in  light
of  the  clinical,  radiological,  and  morphological  features,
using  appropriately  IHC  markers  such  as  GS  and  CRP  whose
interpretation  requires  knowledge  of  underlying  molecu-
lar  pathways;
• there  is  an  urgent  need  to  discuss  the  difﬁculties  in  IHC
interpretation  among  experienced  liver  pathologists  to
assess  the  range  of  varieties  in  the  immunostaining  and  to
avoid  confusion  in  the  diagnosis  of  benign  hepatocellular
tumors.
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